(Update: The NIH provided the following response on July 30, 2021.) Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health’s (NIH) National Cancer Institute (NCI) regarding the “Prospective Grant of an Exclusive Patent License: High ASS1 Expressing… Continue Reading
On Monday, 21 June 2021, Knowledge Ecology International (KEI) delivered the following oral statement to the Open Session of the 23rd Meeting of the WHO Expert Committee on the Selection and Use of Essential Medicines. The program for the open… Continue Reading
At the World Health Organization’s 74th World Health Assembly, Knowledge Ecology International delivered the following remarks on “Public health emergencies: preparedness and response” on Monday, 31 May 2021. Non-state actors are limited to one minute statements. Knowledge Ecology International asks… Continue Reading
(More on the USTR Special 301. link) Attached are links to several of the industry submissions for the 2021 USTR Special 301 list. The Docket: USTR-2020-0041 PhRMA 2021 Special 301 Review Comment, and Correction to Comment BIO 2021 Special 301… Continue Reading
KEI roundtable on pathways to scale up manufacturing capacity for COVID-19 vaccines Friday, 19 February 2021 14h00 UTC to 16h00 UTC 15h00 CET to 17h00 CET 09h00 EST to 11h00 EST On Friday, 19 February 2021, KEI will host a… Continue Reading
The European Commission has released a redacted version of a contract with Curevac for a COVID-19 vaccine. The vaccine uses mRNA technology, similar to the Pfizer and Moderna vaccines. The contract is severely redacted in some areas, but some information… Continue Reading
To: Ken Millburne Technology Transfer Program Food and Drug Administration Via email: Kenneth.millburne@fda.hhs.gov From: James Love Knowledge Ecology International 1621 Connecticut Avenue NW, Suite 500 Washington, DC 20009 https://keionline.org Date: November 30, 2020 Re: Prospective Grant of an Exclusive Patent… Continue Reading
A contract between Regeneron and Advanced Technology International (ATI) involving $450 million in taxpayer funding uses the “Other Transactions Authority” or OTA, to avoid Bayh-Dole safeguards on patent rights. ATI is entering into purchase agreements on behalf of the Department… Continue Reading